-
Reelin–SFK Signaling in Ketamine Synaptic Action
2026-09-14
This PNAS study identifies Reelin–ApoER2–Src family kinase signaling as a permissive pathway for ketamine-induced hippocampal synaptic plasticity and behavioral effects. By combining genetic deletion, pharmacological inhibition, electrophysiology, and biochemical analysis, the authors show that disruption of this pathway compromises baseline NMDA receptor function and blocks ketamine responsiveness in mice.
-
NIH/3T3 Cells: Recovery, Culture, and QC
2026-09-14
NIH/3T3 Cells provide an adherent mouse fibroblast starting material for controlled expansion, cell transfection studies, viral proliferation research, and oncogene research. This product should be used as a research cell model, not as evidence of clinical performance, diagnostic utility, viral permissiveness, or a defined quantitative assay outcome.
-
ISRIB (trans-isomer): PERK Inhibitor Workflows
2026-09-13
ISRIB (trans-isomer) gives researchers a controlled way to separate stress-induced translation shutdown from upstream stress signaling. This workflow-focused guide connects eIF2B-centered ISR inhibition with ER stress, apoptosis assays, and memory-retention experiments, while emphasizing timing, controls, and interpretation limits.
-
CHIR-99021 for Wnt-Controlled Organoid Workflows
2026-09-12
CHIR-99021 (CT99021) gives researchers a selective, time-resolved way to manipulate GSK-3 and Wnt/β-catenin activity in stem-cell and organoid systems. This guide translates the compound into suspension human intestinal organoid workflows, with practical controls, readouts, and troubleshooting for mesothelial differentiation studies.
-
MMP-2 Liposomes for Sequential Cancer Immunotherapy
2026-09-11
The reference study developed NLG919@Lip-pep1, an MMP-2-responsive liposome that sequentially presents the PD-1 pathway-blocking peptide AUNP-12 and the IDO inhibitor NLG919. Its cascade-targeting design coordinated checkpoint relief with remodeling of the immunosuppressive breast cancer microenvironment, providing a useful preclinical framework for combination immunotherapy delivery.
-
O6-Benzylguanine: MGMT Inhibitor Workflow
2026-09-11
O6-Benzylguanine converts MGMT biology into a controllable pharmacology experiment, helping researchers separate DNA repair inhibition from transcriptional regulation. This workflow pairs direct MGMT blockade with alkylating-agent sensitivity, DNA-damage readouts, and the AP-2α findings reported in recurrent glioblastoma.
-
Filipin III: Mapping Cholesterol in Fibrotic Lung Biology
2026-09-10
A translational framework for using Filipin III to connect membrane cholesterol organization with SOAT1-driven macrophage dysfunction and pulmonary fibrosis, while preserving the distinction between spatial cholesterol mapping and therapeutic proof.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-09-10
A 2025 study showed that naturally occurring angiotensin peptides can alter SARS-CoV-2 spike binding to AXL, ACE2, and neuropilin-1 in sequence-dependent ways. Its deletion and residue-modification experiments connect renin–angiotensin peptide processing with viral receptor biology while also defining important limits for interpretation beyond in vitro binding assays.
-
MPS IVA Cartilage Pathology and Lysosomal Exocytosis
2026-09-09
A 2026 Disease Models & Mechanisms study links GALNS deficiency in zebrafish cartilage to enhanced lysosomal exocytosis, reduced cathepsin activity, altered glycosaminoglycan distribution, and weakened TGFβ/BMP signaling. The work shows that similar trafficking abnormalities can produce disorder-specific biochemical outcomes, refining how lysosomal storage disorders are interpreted beyond substrate accumulation alone.
-
TSPAN18, STIM1, and Prostate Cancer Bone Metastasis
2026-09-09
Zhou et al. identify TSPAN18 as a previously unrecognized regulator of STIM1 stability in prostate cancer. By competing with TRIM32-mediated ubiquitination, TSPAN18 sustains STIM1-dependent calcium entry and promotes migration, invasion, and bone metastasis, providing a mechanistic link between protein turnover and metastatic signaling.
-
Deracoxib Workflows for Canine COX-2 Research
2026-09-08
Deracoxib combines selective COX-2 inhibition with practical readouts for canine inflammation, pain, and oncology studies. This guide translates a canine mammary-cell combination study into reproducible viability, apoptosis, and nitric oxide workflows while highlighting solvent control, model selection, and translational limits.
-
O6-Benzylguanine: MGMT Inhibitor Workflows
2026-09-08
O6-Benzylguanine provides a pharmacological route to suppress MGMT-mediated DNA repair and test whether alkylating-agent resistance is repair-dependent. This workflow combines controlled pretreatment, orthogonal DNA-damage readouts, and troubleshooting strategies for cancer chemotherapy research.
-
DR5 Agonists and PD-L1 Immune Evasion in Solid Tumors
2026-09-07
Mondal and colleagues identified an unexpected immune-evasion pathway triggered by clinical DR5 agonist antibodies: caspase-8 signaling activates ROCK1 and weakens proteasome function, stabilizing tumor-cell PD-L1. The study shows that interrupting the DR5–ROCK1–PD-L1 axis can improve effector T-cell activity and antitumor responses, offering a mechanistic rationale for combination strategies in solid tumors.
-
CIP2A, PKM2 Tetramers, and NSCLC Oxidative Phosphorylation
2026-09-07
The reference study identifies CIP2A as a metabolic regulator in non-small cell lung cancer, showing that it binds PKM2, promotes PKM2 tetramer formation through phosphorylation at S287, and redirects pyruvate metabolism toward mitochondrial oxidative phosphorylation. Its findings connect CIP2A-dependent metabolic plasticity with Bcl2 regulation and suggest that combined targeting of CIP2A and glycolysis may suppress tumor growth.
-
Lysosomal Exocytosis in MPS IVA Cartilage
2026-09-05
The reference study identifies enhanced lysosomal exocytosis as a contributor to cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA, extending the disease mechanism beyond macromolecular storage. Its comparison with sialidosis reveals that increased exocytosis can produce disease-specific changes in cathepsin activity, glycosaminoglycan distribution, and TGFβ/BMP signaling.